694 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
LLY Eli Lilly and Company $105.71 $113.53B N/A
Article Searches
Lilly's Breast Cancer Drug Gets Priority Review Status by FDA http://www.zacks.com/stock/news/267140/lillys-breast-cancer-drug-gets-priority-review-status-by-fda?cid=CS-ZC-FT-267140 Jul 11, 2017 - Eli Lilly and Company (LLY) announced that its new drug application for its pipeline candidate, abemaciclib , has been accepted for priority review by the FDA for patients with advanced breast cancer.
Better Buy: Pfizer Inc. vs. Eli Lilly and Company https://www.fool.com/investing/2017/07/01/better-buy-pfizer-inc-vs-eli-lilly-and-company.aspx?source=iedfolrf0000001 Jul 01, 2017 - Which big pharma stock wins in a head-to-head matchup between Pfizer and Lilly?
Novartis Gets EC Nod for Lung Cancer Drug's Label Expansion http://www.zacks.com/stock/news/266033/novartis-gets-ec-nod-for-lung-cancer-drugs-label-expansion?cid=CS-ZC-FT-266033 Jun 29, 2017 - Novartis AG (NVS) announced that the European Commission has approved a label expansion of lung cancer drug drug Zykadia.
Better Buy: Eli Lilly and Co. vs. Merck & Co., Inc. https://www.fool.com/investing/2017/06/27/better-buy-eli-lilly-and-company-vs-merck.aspx?source=iedfolrf0000001 Jun 27, 2017 - Find out which of these pharmaceutical stocks is the best pick right now.
Why Alder Biopharma Stock Is Crashing Today https://www.fool.com/investing/2017/06/27/why-alder-biopharma-stock-is-crashing-today.aspx?source=iedfolrf0000001 Jun 27, 2017 - Disappointing phase 3 trial results are increasing concerns that its migraine drug might not be a commercial success.
Why You Should Add Novo Nordisk Stock to Your Portfolio http://www.zacks.com/stock/news/265294/why-you-should-add-novo-nordisk-stock-to-your-portfolio?cid=CS-ZC-FT-265294 Jun 22, 2017 - Novo Nordisk (NVO) is healthcare company and a with leadership in the global diabetes market. It looks like a great stock to buy now.
Could Legalized Marijuana Be Making Big Pharma Nervous? https://www.fool.com/investing/2017/06/18/could-legalized-marijuana-be-making-big-pharma-ner.aspx?source=iedfolrf0000001 Jun 18, 2017 - A new report says that drugmakers could lose billions of dollars per year if marijuana is legalized throughout the U.S. Should Pfizer, Allergan, and others be nervous?
5 Answers to Questions Gilead Sciences' Investors Probably Have https://www.fool.com/investing/2017/06/18/5-answers-to-questions-gilead-sciences-investors-p.aspx?source=iedfolrf0000001 Jun 18, 2017 - Gilead Sciences executives provide some answers at the Goldman Sachs healthcare conference.
Johnson & Johnson's Type 2 Diabetes Drug Is Stellar in Cardiovascular Trials, but Comes With a Catch https://www.fool.com/investing/2017/06/15/johnson-johnsons-type-2-diabetes-drug-is-stellar-i.aspx?source=iedfolrf0000001 Jun 15, 2017 - Invokana matches and tops Jardiance in some respects, but this major side effect could be tough to overcome.
Why Is ImmunoGen (IMGN) Stock Up 131% This Year? http://www.zacks.com/stock/news/264477/why-is-immunogen-imgn-stock-up-131-this-year?cid=CS-ZC-FT-264477 Jun 15, 2017 - Shares of ImmunoGen, Inc. (IMGN) are massively up 130.9% this year so far, outperforming the the Zacks classified Medical-Drugs industry's registered 3.6% increase during this period.

Pages: 1...5354555657585960616263...70

<<<Page 58>